Patient Advocacy: Under the Influence of Big Pharma?

Beginning in the early 1990s, as state-funding dried out, patient advocacy groups - collectives meant to express the needs of those suffering from serious diseases - were co-opted by pharmaceutical companies offering money in exchange for influence. So says author Sharon Batt, who details big pharma's supposed interference in her new book, "Health Advocacy Inc." Steve Paikin talks to her about the extent of this encroachment, and whether it has compromised Canada's patient advocacy organizations.